ALLMedicine™ Burkitt Lymphoma Center

Mar 23rd, 2023 - The purpose of this study is to test any good and bad effects of the study drug, CPI-613.

Mar 21st, 2023 - To analyze the factors associated with survival in the largest cohort of individuals with HIV and lymphoma so far described in Brazil. A retrospective, observational, multicenter study involving five institutions in São Paulo, Brazil. The medical ...

Mar 21st, 2023 - Non-radiographic axial spondyloarthropathy (nr-axSpA) is a clinical diagnosis of symptoms matching inflammatory back pain criteria without radiological lesions at the sacroiliac joint. The frequency of an early nr-axSpA-like presentation in lympho...

Mar 18th, 2023 - People living with HIV (PLWH) have elevated risk of non-Hodgkin lymphoma (NHL) and other diseases. Studying clonal hematopoiesis (CH), the clonal expansion of mutated hematopoietic stem cells, could provide insights regarding elevated NHL risk. Co...

Mar 11th, 2023 - Primary mediastinal B-cell lymphoma (PMBCL) is a rare but aggressive mature B-cell lymphoma that arises from thymic B cells and most commonly affects adolescents and young adults. PMBCL is now recognized by the WHO as a distinct entity from diffus...

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

Mar 23rd, 2023 - The purpose of this study is to test any good and bad effects of the study drug, CPI-613.

Mar 10th, 2023 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...

Mar 10th, 2023 - The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of rela...

Mar 6th, 2023 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

Feb 24th, 2023 - This is a Phase 1b, multi-center, open-label, multi-arm study to evaluate the safety and anti-cancer activity of loncastuximab tesirine in combination with gemcitabine, lenalidomide, polatuzumab vedotin, or umbralisib in participants with relapsed...

Oct 17th, 2022 - The FDA has granted an orphan drug designation (ODD) to PCLX-001 (DDD86481) for the treatment of patients with acute myeloid leukemia (AML).1 PCLX-001 is a first-in-class N-myristoylation (NMT) inhibitor that is currently being studied in non-H...

Aug 24th, 2022 - The FDA has accepted a supplemental biologics license application (sBLA) for the combination of polatuzumab vedotin-piiq (Polivy) and R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) as a treatment for patients with previ...

Aug 12th, 2022 - A substantial proportion of gastric cancers worldwide was linked with the Epstein-Barr virus (EBV), according to a meta-analysis. In a pooled analysis involving over 68,000 patients with conventional gastric adenocarcinoma in 37 countries, EBV pre...

Jun 12th, 2022 - Treatment with the R-CODOX-M and R-IVAC regimens elicited similar efficacy to dose-adjusted infused DA-EPOCH-R in patients with newly diagnosed, high-risk Burkitt lymphoma, according to results from a phase 3 trial (EUDRACT 2013-004394-27).1 Study...

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....